Untangling the cost-effectiveness knot: Who is oral antiretroviral HIV pre-exposure prophylaxis really for?

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 14, Issue 2, 2014, Pages 167-170

  Hankins, Catherine A ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antiretroviral drugs; Cost effectiveness; HIV prevention; Pre exposure prophylaxis

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; HEALTH CARE POLICY; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PROGRAM DEVELOPMENT; REVIEW; RISK ASSESSMENT; RISK FACTOR; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; ECONOMICS; HIV INFECTIONS; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; HIV INFECTIONS; HUMANS;

EID: 84896298377     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2014.887447     Document Type: Review

References (23)

1. UN AIDS. Global Report. UNAIDS Report on the Global AIDS Epidemic 2013 [Internet]. Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland. 2013. Available from: www.unaids.org/en/media/unaids/contentassets/documents/ epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en.pdf
2. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363(27):2587-99
3. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367(5):399-410
4. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367(5): 423-34
5. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013;381(9883):2083-90
6. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012;367(5):411-22
7. Microbicides Trial Network. MTN statement on decision to discontinue use of oral tenofovir tablets in VOICE, a major HIV prevention study in women [Internet]. Pittsburgh, PA, USA. 2011. Available from: www.mtnstopshiv.org/node/ 3619
8. Van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 2012; 26(7):F13-19
9. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012;4(151):151ra125
10. Gomez GB, Borquez A, Case KK, et al. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med 2013;10(3):e1001401
11. Macklin R, Cowan E. Given financial constraints, it would be unethical to divert antiretroviral drugs from treatment to prevention. Health Aff 2012;31(7):1537-44
12. Jonsen AR. Bentham in a box: technology assessment and health care allocation. Law Med Heal Care 1986;14(3-4):172-4
13. Brock DW, Wikler D. Ethical challenges in long-term funding for HIV/AIDS. Health Aff 2009;28(6):1666-76
14. Cohen MS, McCauley M, Sugarman J. Establishing HIV treatment as prevention in the HIV Prevention Trials Network 052 randomized trial: an ethical odyssey. Clin Trials 2012;9(3):340-7
15. Walensky RP, Ross EL, Kumarasamy N, et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med 2013;369(18):1715-25
16. Babiker AG, Emery S, Fätkenheuer G, et al. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials 2013;10(1 Suppl): S5-S36
17. The START Study [Internet]. Available from: www.thestartstudy.org/ learnmore.html [Last assessed 19 July 2013]
18. Hirnschall G, Harries AD, Easterbrook PJ, et al. The next generation of the World Health Organization's global antiretroviral guidance. J Int AIDS Soc 2013;16:18757
19. Brandeau ML. OR in public health: A little help can go a long way. Oper Res Heal Care Policy (Chap. 2). Springer; New York, NY, USA: 2013. p. 17-38
20. US FDA. FDA, Press release: FDA approves first drug for reducing the risk of sexually acquired HIV infection [Internet]. Silver Spring: U.S. Food and Drug Administration. 2012. Available from: www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm312210.htm
21. WHO. Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV. Recommendations for use in the context of demonstration projects [Internet]. 2012; Available from: www.who.int/hiv/pub/guidance-prep/en/index.html
22. Hankins CA, de Zalduondo BO. Combination prevention: a deeper understanding of effective HIV prevention. AIDS 2010;24(Suppl 4):S70-80
23. Amico KR, Mansoor LE, Corneli A, et al. Adherence Support Approaches in Biomedical HIV Prevention Trials: experiences, Insights and Future Directions from Four Multisite Prevention Trials. AIDS Behav 2013;17(6):2143-55